Greg Merril is CEO of Adaptive Phage Therapeutics – which he co-founded in 2016 with his father, noted phage researcher, Carl Merril. Greg is a serial life-science entrepreneur, recognized by Ernst & Young as a regional Entrepreneur of the Year winner. As prior founding CEO of Immersion Medical (NASDQ: IMMR) he led the creation of the world’s first commercially successful virtual reality surgical training simulators resulting in a company that was one of Maryland’s fastest revenue growth technology firms for four consecutive years. IMMR had peak market capitalization of over $1 billion. Greg has been recognized as a TEDMED Innovation Scholar for his work developing and commercializing head impact sensor technology to address the issue of sports-related traumatic brain injury. During his career Greg’s product developed efforts have been recognized twice as Innovation of the Year by the Consumer Electronic Association (CEA)/ Industrial Designers Society of America (IDSA). Other awards have included the 2015 International Sports Technology Award for Best Wearable Technology, and his previous company was selected as a Wall Street Journal Startup Company of the Year.